Go Pro
→ This metric called 1929, 1969 and 2000 [it's screaming now] (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionomics Limited stock logo
BNOX
Bionomics
$0.25
$0.27
$0.18
▼
$0.94
$4.47M0.266.12 million shsN/A
HIND
Vyome
$2.20
+1.6%		$2.18
$1.75
▼
$10.97
$15.16M1.489,303 shs2,221 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.81
-0.5%		$1.23
$0.59
▼
$1,030.00
$15.78M-2.2669,175 shs32,187 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$1.08
$1.03
$0.84
▼
$12.23
$17.86M-1.72284,714 shs69,440 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionomics Limited stock logo
BNOX
Bionomics
0.00%0.00%0.00%0.00%0.00%
HIND
Vyome
+1.62%-3.73%+10.30%-6.20%+219,499,900.00%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-0.49%-3.33%+23.01%-63.58%-99.83%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%+5.88%+24.00%-29.41%-89.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionomics Limited stock logo
BNOX
Bionomics
$0.25
$0.27
$0.18
▼
$0.94
$4.47M0.266.12 million shsN/A
HIND
Vyome
$2.20
+1.6%		$2.18
$1.75
▼
$10.97
$15.16M1.489,303 shs2,221 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.81
-0.5%		$1.23
$0.59
▼
$1,030.00
$15.78M-2.2669,175 shs32,187 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$1.08
$1.03
$0.84
▼
$12.23
$17.86M-1.72284,714 shs69,440 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionomics Limited stock logo
BNOX
Bionomics
0.00%0.00%0.00%0.00%0.00%
HIND
Vyome
+1.62%-3.73%+10.30%-6.20%+219,499,900.00%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-0.49%-3.33%+23.01%-63.58%-99.83%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%+5.88%+24.00%-29.41%-89.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionomics Limited stock logo
BNOX
Bionomics
0.00
N/AN/AN/A
HIND
Vyome
2.40
Hold$15.00583.37% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
2.00
Hold$1,158.33142,534.32% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest BNOX, TPST, KALA, and HIND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionomics Limited stock logo
BNOX
Bionomics
$10K446.82N/AN/A$1.32 per share0.19
HIND
Vyome
$129.73K118.75N/AN/A$1.04 per share2.11
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/A$0.47 per shareN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionomics Limited stock logo
BNOX
Bionomics
-$15.49MN/AN/AN/AN/AN/AN/AN/AN/A
HIND
Vyome
-$10.26M-$3.37N/AN/AN/A-3,024.84%-197.33%-138.14%N/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$26.98M-$31.96N/AN/AN/AN/A-222.35%-70.23%11/10/2026 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)

Latest BNOX, TPST, KALA, and HIND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$6.00-$21.32-$15.32-$21.32$25.00 millionN/A
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
8/12/2026Q2 2026
HIND
Vyome
N/A-$0.10N/A-$0.10N/A$0.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bionomics Limited stock logo
BNOX
Bionomics
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionomics Limited stock logo
BNOX
Bionomics
N/A
3.30
3.30
HIND
Vyome
N/A
4.37
4.37
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/A
6.88
6.88
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
Bionomics Limited stock logo
BNOX
Bionomics
15.90%
HIND
Vyome
22.06%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
Bionomics Limited stock logo
BNOX
Bionomics
0.69%
HIND
Vyome
33.00%
KALA BIO, Inc. stock logo
KALA
KALA BIO
2.24%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionomics Limited stock logo
BNOX
Bionomics
N/A17.65 million17.53 millionNot Optionable
HIND
Vyome
507.02 million4.70 millionN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
3019.34 million18.91 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2016.54 million10.55 millionNo Data

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
August 13, 2026  |  quiverquant.comQ
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344974/0/en/tempest-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330290/0/en/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-t.html
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial
July 15, 2026  |  quiverquant.comQ
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html
Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  quiverquant.comQ
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307117/0/en/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors.html
Tempest Therapeutics Announces Resignation of Board Director
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-resignation-of-board-director?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants
May 29, 2026  |  quiverquant.comQ
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303540/0/en/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds.html
Tempest Therapeutics Announces Multiple Board Director Resignations
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-multiple-board-director-resignations?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505685-tempest-therapeutics-tempest-reports-first-quarter-2026-financial-results-and-provides-business-update-399.htm
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295395/0/en/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update.html
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288654/0/en/tempest-presents-clinical-update-at-isct-2026-annual-meeting.html
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283678/0/en/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting.html
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t.html
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273302/0/en/tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts.html
New Strong Buy Stocks for April 10th
April 10, 2026  |  zacks.comhttps://www.zacks.com/commentary/2897019/new-strong-buy-stocks-for-april-10th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bionomics stock logo

Bionomics NASDAQ:BNOX

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Vyome NASDAQ:HIND

$2.19 +0.04 (+1.62%)
Closing price 08/27/2026 03:56 PM Eastern
Extended Trading
$2.22 +0.02 (+1.05%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$0.81 0.00 (-0.49%)
Closing price 08/27/2026 03:58 PM Eastern
Extended Trading
$0.85 +0.04 (+4.54%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$1.08 0.00 (0.00%)
Closing price 08/27/2026 04:00 PM Eastern
Extended Trading
$1.08 +0.00 (+0.46%)
As of 07:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas